Mar 7 |
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
|
Mar 5 |
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909
|
Feb 28 |
Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock?
|
Feb 28 |
Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference
|
Feb 12 |
Foghorn Therapeutics Inc. (FHTX) Moves 22.7% Higher: Will This Strength Last?
|
Feb 9 |
Foghorn (FHTX) Jumps 55% as Lilly Takes Up FHD-909 Development
|
Feb 8 |
Foghorn says Eli Lilly picked lung cancer candidate for further studies
|
Feb 8 |
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor
|
Jan 11 |
With 39% stake, Foghorn Therapeutics Inc. (NASDAQ:FHTX) seems to have captured institutional investors' interest
|
Jan 8 |
Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024
|